DOCSLIB.ORG

Report of the Joint Working Group on Quantitative in Vivo Functional Imaging in Oncology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Report of the Joint Working Group on Quantitative in Vivo Functional Imaging in Oncology Report of the Joint Working Group on Quantitative In Vivo Functional Imaging in Oncology January 6–8, 1999 Washington, D.C. Sponsored by the U.S. Public Health Service’s Office on Women’s Health and National Cancer Institute Editors Faina Shtern, M.D. Daniel Winfield, M.S. U.S. Public Health Service Research Triangle Institute Office on Women’s Health Contributors Britton Chance, Ph.D., D.Sc. Steven E. Harms, M.D. University of Pennsylvania Medical Center University of Arkansas for Medical Sciences Jerry M. Collins, Ph.D. Rakesh K. Jain, Ph.D. U.S. Food and Drug Administration Harvard University Medical School William C. Eckelman, Ph.D. Stephen Lam, M.D., F.R.C.P.C. National Institutes of Health Clinical Center University of British Columbia Jeffrey L. Evelhoch, Ph.D. James L. Mulshine, M.D. Wayne State University National Cancer Institute Michael S. Feld, Ph.D. Richard L. Wahl, M.D. Massachusetts Institute of Technology University of Michigan John N. Weinstein, M.D., Ph.D. National Cancer Institute Acknowledgments Daniel Sullivan, M.D. Wanda K. Jones, Dr.P.H. Robert E. Wittes, M.D. National Cancer Institute U.S. Public Health Service National Cancer Institute Office on Women’s Health Contents Planning Committee ...................................................................................................................................................iv Speakers and Panelists ................................................................................................................................................v Introduction .................................................................................................................................................................1 Goals of the Joint USPHS OWH/NCI Working Group .............................................................................................1 References ..................................................................................................................... ............................................3 Session 1: Summary of Clinical Issues .......................................................................................................................4 Breast Cancer.............................................................................................................................................................4 Lung Cancer...............................................................................................................................................................5 Prostate Cancer ................................................................................................................ ..........................................7 Colorectal Carcinoma ........................................................................................................... .....................................7 Esophageal Cancer.....................................................................................................................................................8 Ovarian Cancer ................................................................................................................. .........................................9 Cervical Cancer ................................................................................................................ .........................................9 Endometrial Cancer ............................................................................................................. ....................................10 Research Priorities............................................................................................................ .......................................10 References ..................................................................................................................... ..........................................11 Session 2: State of the Art in Functional Imaging...................................................................................................16 MRI/MRS ................................................................................................................................................................16 Nuclear Medicine and PET Imaging........................................................................................................................17 Optical Imaging Methods ........................................................................................................ ................................20 Electron Paramagnetic Resonance Imaging........................................................................................ .....................21 Research Priorities and Overall Recommendations .................................................................................................22 References ..................................................................................................................... ..........................................25 Session 3: Tumor Biology/Pathology........................................................................................................................26 Oncology, Tumor Biology, and Pathophysiology....................................................................................................26 Optical Imaging and Spectroscopy ..........................................................................................................................27 Magnetic Resonance Imaging and Spectroscopy.....................................................................................................28 Nuclear Medicine and PET......................................................................................................................................28 Key Findings and Recommendations.......................................................................................................................29 Research Priorities ...................................................................................................................................................30 References ...............................................................................................................................................................31 Session 4: Pharmacology ...........................................................................................................................................33 Positron Emission Tomography...............................................................................................................................33 Magnetic Resonance Imaging..................................................................................................................................34 Optical Methods in Site-Specific Pharmacokinetics ................................................................................................35 In Vivo Optical Applications ...................................................................................................................................35 Pharmacology without Imaging Tools .....................................................................................................................36 Research Priorities ...................................................................................................................................................36 References ...............................................................................................................................................................36 Quantitative In Vivo Functional Imaging ii January 6–8, 1999 Session 5: Cellular and Molecular Targets..............................................................................................................38 Biological Targets for Functional Imaging ..............................................................................................................38 Monitoring In Vivo Gene Expression with MRI .....................................................................................................38 Tumor Biology and Physiology ...............................................................................................................................38 Using Tumor Biology to Map Gene Expression......................................................................................................39 Targets for Optical Spectroscopy and Imaging........................................................................................................39 Targets for Nuclear Medicine/PET..........................................................................................................................40 Evaluation of Gene Therapy and Signal Transduction Pathways ............................................................................41 Using Carbon-11-Thymidine in Evaluating Renal Cancer.......................................................................................41 Research Priorities ...................................................................................................................................................42 References ...............................................................................................................................................................43 Quantitative In Vivo Functional Imaging iii January 6–8, 1999 Planning Committee The U.S. Public Health Service’s Office on Women’s Health and the National Cancer Institute gratefully acknowledge the members of the planning committee, who devoted time and effort
Load more

Recommended publications
  • Advances in Optics for Biotechnology, Medicine and Surgery XV
    Program Advances in Optics for Biotechnology, Medicine and Surgery XV July 23 - 26, 2017 Westin Snowmass Snowmass Village, Colorado, USA Conference Chairs Peter So Massachusetts Institute of Technology, USA Kate Bechtel Triple Ring Technologies, USA Ivo Vellekoop University of Twente, The Netherlands Michael Choma Yale University, USA Engineering Conferences International 32 Broadway, Suite 314 - New York, NY 10004, USA www.engconfintl.org – [email protected] The Westin Snowmass Resort 100 Elbert Lane, PO Box 5009 Snowmass Village, Colorado, 81615 United States +1-970-923-8200 Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines. ECI BOARD MEMBERS Barry C. Buckland, President Mike Betenbaugh Nick Clesceri Peter Gray Michael King Raymond McCabe David Robinson Eugene Schaefer P. Somasundaran Chair of ECI Conferences Committee: Nick Clesceri ECI Technical Liaison for this conference: Brian Wilson ECI Executive Director: Barbara K. Hickernell ECI Associate Director: Kevin M. Korpics ©Engineering Conferences International Previous conferences in this series: Future Directions for Lasers in Medicine and Surgery February 26-March 3, 1989 Palm Coast, Florida Conference Chairs: Ronald W. Waynant, FDA, USA Ashley J. Welch, University of Texas-Austin, USA Future Directions for Lasers in Medicine and Surgery II February 24-March 1, 1991 Palm Coast, Florida Conference Chairs: Thomas F. Deutsch, Wellman Labs, MA General, USA Ronald W. Waynant, FDA/CDRH, USA Future Directions for Lasers in Medicine and Surgery III February 27-March 4, 1993 Palm Coast, Florida Conference Chair: Joseph T.
    [Show full text]
  • Conference Brochure
    Program Advances in Optics for Biotechnology, Medicine and Surgery XVI June 2-5, 2019 Fairmont Tremblant Mont Tremblant, Quebec, Canada Conference Co-Chairs Erin Buckley Emory University/Georgia Institute of Technology, USA Christophe Moser Polytechnique Fédérale de Lausanne (EPFL), Switzerland Brian Pogue Dartmouth College, USA David Sampson University of Surrey, United Kingdom Engineering Conferences International 32 Broadway, Suite 314 - New York, NY 10004, USA www.engconfintl.org – [email protected] Fairmont Tremblant 3045 Chemin de la Chapelle Mont-Tremblant Québec J8E 1E1 Canada Telephone: +1-819-681-7000 Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines. ECI BOARD MEMBERS Barry C. Buckland, President Mike Betenbaugh Joye Bramble Nick Clesceri Peter Gray Michael King Raymond McCabe Eugene Schaefer P. Somasundaran Chair of ECI Conferences Committee: Nick Clesceri ECI Technical Liaison for this conference: Brian Wilson ECI Executive Director: Barbara K. Hickernell ECI Associate Director: Kevin M. Korpics ©Engineering Conferences International Previous conferences in this series: Future Directions for Lasers in Medicine and Surgery February 26-March 3, 1989 Palm Coast, Florida Conference Chairs: Ronald W. Waynant, FDA, USA Ashley J. Welch, University of Texas-Austin, USA Future Directions for Lasers in Medicine and Surgery II February 24-March 1, 1991 Palm Coast, Florida Conference Chairs: Thomas F. Deutsch, Wellman Labs, MA General, USA Ronald W. Waynant, FDA/CDRH, USA Future Directions for Lasers in Medicine and Surgery III February 27-March 4, 1993 Palm Coast, Florida Conference Chair: Joseph T.
    [Show full text]
  • Ripe Opportunities for Regional Collaboration in East Asia
    26 July 2001 Nature 412: 6845 (2001) © Macmillan Publishers Ltd. Ripe opportunities for regional collaboration in east 361 Asia East Asian collaboration in molecular biology could enhance the scientific viability of the region, but it requires more enthusiastic support from potential participants — particularly Japan. Back from the brink 361 The government's threat to suspend clinical trials at America's largest medical school highlights an impasse over funding. Johns Hopkins researchers fume over government 363 crackdown Drugs approval process gets speed treatment 364 Scientists fear new guidelines will stifle basic research 364 'Political fix' saves Kyoto deal from collapse 365 US rejects bioweapon inspections 365 Author of anti-encryption program faces jail 366 NASA mission has wind in its sails 366 Physicists rally behind linear-collider plan 367 Sea lions massacred in Galapagos for sex organs 367 news in brief 368 Building a biopolis 370 Having established itself as a financial and manufacturing centre, Singapore now wants to become a leading player in advanced biological research. David Cyranoski assesses the scientific ambitions of a vibrant city-state. Picture perfect 372 Medical imaging techniques are being adapted to study gene expression and other cellular activities in living animals. Corie Lok talks to the pioneers who are watching cells at work in their natural habitat. Framework welcome, but could do with fine-tuning 375 Let's get details sorted out, timescales defined, postdocs funded, entrepreneurs trained. Climate-change strategy needs to be robust 375 When three's not a crowd 375 Medicine as performance 377 JOHN HARLEY WARNER reviews Bodies Politic: Disease, Death and Doctors in Britain, 1650–1900 by Roy Porter Early British modern medicine can be considered as a type of theatre.
    [Show full text]
  • Sparking Economic Growth
    100 SUCCESS STORIES SPARKING ECONOMIC GROWTH How federally funded university research creates innovation, GOVERNMENT FUNDING new companies + and jobs UNIVERSITY RESEARCH = INNOVATION, COMPANIES, JOBS APRIL 2010 www.sciencecoalition.org ABOUT THIS REPORT This report was prepared by The Science Coalition (TSC) to illustrate one way in which federal investment in basic research helps to stimulate the economy. The examples highlighted were provided by the member universities of The Science Coalition (each member was invited to submit a small number of examples). They tell an important story about the role federally funded university-based research plays in the economy of the United States. The companies listed represent only a small sampling of the many companies that are the result of federally funded university-based research. This report is provided for illustrative purposes. The information about the companies was collected in 2009. The Science Coalition is a nonprofit, nonpartisan organization of more than 40 of the nation’s leading public and private research universities. It is dedi- cated to sustaining the federal government’s investment in basic research as a means to stimulate the economy, drive innovation and secure America’s global competitiveness. More information about The Science Coalition is available at www.sciencecoalition.org. The Science Coalition: Sparking Economic Growth 1 EXECUTIVE SUMMARY I The federal government is the primary source of funding for basic research conducted in the United States, providing some 60 percent of funding. The second largest source of basic research funding is the academic institutions themselves. I Universities conduct the majority of basic research in the United States — 55 percent in 2008.
    [Show full text]
  • Conference Program Peter So Massachusetts Ni Stitute of Technology, USA
    Engineering Conferences International ECI Digital Archives Advances in Optics for Biotechnology, Medicine Proceedings and Surgery XV 7-23-2017 Conference Program Peter So Massachusetts nI stitute of Technology, USA Kate Bechtel Triple Ring Technologies, USA Ivo Vellekoop University of Twente, The Netherlands Michael Choma Yale University, USA Follow this and additional works at: http://dc.engconfintl.org/biotech_med_xv Part of the Engineering Commons Recommended Citation Peter So, Kate Bechtel, Ivo Vellekoop, and Michael Choma, "Conference Program" in "Advances in Optics for Biotechnology, Medicine and Surgery XV", Peter So, Massachusetts nI stitute of Technology, USA Kate Bechtel, Triple Ring Technologies, USA Ivo Vellekoop, University of Twente, The eN therlands Michael Choma, Yale University, USA Eds, ECI Symposium Series, (2017). http://dc.engconfintl.org/biotech_med_xv/41 This Article is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Advances in Optics for Biotechnology, Medicine and Surgery XV by an authorized administrator of ECI Digital Archives. For more information, please contact [email protected]. Program Advances in Optics for Biotechnology, Medicine and Surgery XV July 23 - 26, 2017 Westin Snowmass Snowmass Village, Colorado, USA Conference Chairs Peter So Massachusetts Institute of Technology, USA Kate Bechtel Triple Ring Technologies, USA Ivo Vellekoop University of Twente, The Netherlands Michael Choma Yale University, USA Engineering Conferences International 32 Broadway, Suite 314 - New York, NY 10004, USA www.engconfintl.org – [email protected] The Westin Snowmass Resort 100 Elbert Lane, PO Box 5009 Snowmass Village, Colorado, 81615 United States +1-970-923-8200 Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.
    [Show full text]
  • Advances in Optics for Biotechnology, Medicine, and Surgery XIV
    Program Advances in Optics for Biotechnology, Medicine, and Surgery XIV June 14-17, 2015 Vail, Colorado, USA Conference Chairs Rainer Leitgeb, PhD Medical University of Vienna, Austria Richard Levenson, MD University of California – Davis, USA Laura Waller, PhD University of California, Berkeley, USA Engineering Conferences International 32 Broadway, Suite 314 - New York, NY 10004, USA Phone: 1 - 212 - 514 – 6760 www.engconfintl.org – [email protected] Vail Cascade Resort & Spa 1300 Westhaven Drive Vail, Colorado 81657 Tel: +1- 970-476-7111 Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines. ECI BOARD MEMBERS Barry C. Buckland, President Mike Betenbaugh Nick Clesceri Peter Gray Michael King Raymond McCabe David Robinson Eugene Schaefer P. Somasundaran Chair of ECI Conferences Committee: Nick Clesceri ECI Technical Liaison for this conference: Brian Wilson ECI Executive Director: Barbara K. Hickernell ECI Associate Director: Kevin M. Korpics ©Engineering Conferences International Previous conferences in this series: Future Directions for Lasers in Medicine and Surgery February 26-March 3, 1989 Palm Coast, Florida Conference Chairs: Ronald W. Waynant, FDA, USA Ashley J. Welch, University of Texas-Austin, USA Future Directions for Lasers in Medicine and Surgery II February 24-March 1, 1991 Palm Coast, Florida Conference Chairs: Thomas F. Deutsch, Wellman Labs, MA General, USA Ronald W. Waynant, FDA/CDRH, USA Future Directions for Lasers in Medicine and Surgery III February 27-March 4, 1993 Palm Coast, Florida Conference Chair: Joseph T.
    [Show full text]
  • Board of Directors Meeting
    BOARD OF DIRECTORS MEETING December 15, 2016 CSIS Building WASHINGTON, D.C. PERSONALIZED MEDICINE COALITION BOARD MEETING December 15, 2016 10:00 a.m. to 2:00 p.m. CSIS Building Washington, D.C. 9th Floor Turret Room Agenda Chairman’s Report 1. Approval of May 25, 2016 Minutes 2. Nominations Committee President’s Report 3. 2016 Progress Report 4. Plans for 2017 5. Finance and Budget 6. Membership 7. Public Policy 8. Science Policy 9. Communications New Business December 2016 Board Meeting Table of Contents Agenda 1. Minutes – May 25, 2016 2. Nominations • Current Board Members • Board Composition by Category • Board of Directors Duties • Bylaws 3. Progress Report • 2016 Progress Report • Conference Program (back pocket) 4. Plans for 2017 • Strategic Plan for 2017 • Clinical and Economic Value of Next-Generation Sequencing • The Personalized Medicine Education Initiative • International Comparative Landscape Analysis • Evidence for Coverage and Payment of Personalized Medicine Diagnostics • Personalized Medicine in Value Assessment Frameworks • Turning the Tide Against Cancer 2017 Conference Prospectus • CRD Proposal: Public Policy • Jen Leib Biography • PMC Vice President, Public Policy: Job Description • Kayla Smith Resume 5. Finance and Budget • 2017 Budget • Historical Budget • 2016 Sponsorships • Friends of PMC • Cash and Investments • Chart: Revenues & Expenses • Chart: Membership & Financial Performance • Chart: Cumulative Net Assets • Investment Detail 6. Membership Status • Chart: PMC Membership Numbers • Dues Schedule for Members and Sponsors • Organizations that have withdrawn from PMC since 2007 • Chart: Analysis of 2015 and 2016 Membership Non-Renewal by Reason • 2016 and 2017 New Members • Target List for 2017 Membership • List of PMC Members • Chart: PMC Membership Numbers by Category • 2016 Sponsorships 7.
    [Show full text]